A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

NCT06246916 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

560

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: fianlimab
DRUG: cemiplimab
DRUG: relatlimab+nivolumab

Sponsor

Regeneron Pharmaceuticals